Cui Zhen, Liu Wen, Zhou Yan, Wang Chao-Ge, Liu Jing-Jing, Li Duo-Jie, Jiang Hao
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016 Jul;36(7):810-813.
To observe the curative effect of Jiedu Shengji Recipe (JSR) in preventing and treating acute radiation esophagitis in radiotherapy induced esophageal carcinoma patients.
Totally 86 mid-late stage esophageal carcinoma patients were assigned to the treatment group and the control group according to random digit table, 43 in each group. All patients received concurrent radiochemotherapy. Patients in the treatment group took JSR from starting the radiotherapy, one dose per day for 8 successive weeks, while those in the control group took mixture of dexamethasone, lido- caine, and gentamicin, 10 mL each time, taken before radiation and within 30 min after radiation, discontinued till the end of radiation. The occurrence time of acute radiation esophagitis and, duration of symptoms, esophageal radioactive damage degree, curative effect, improvement rate of Karnofsky performance scale (KPS) , and the incidence of adverse reactions were observed in the two groups.
Compared with the control group, the occurrence time of acute radiation esophagitis was prolonged (15. 46±3. 37 days vs 10.23±2.46 days) , and duration of symptoms was shortened (20.18±4.56 days vs 26. 17±3. 26 days) in the treatment group, with statistical difference (P <0. 01). In the treatment group the occurrence rate of mid and high level (degree II to degree IV) acute radiation esophagitis was lower than that of the control group (Z =3. 34, P <0. 01). The total effective rate was 95. 35% (41/43) in the treatment group and 67. 44% (29/43) in the control group, with statistical difference between the two groups (X² =11.06, P<0.01 ). The improvement rate of KPS were higher in the treatment group than in the control group [65. 12% (28/43) vs 27.91% (12/43) ; X² =11.97, P <0. 01]. The incidence of adverse reactions were lower in the treatment group than in the control group with statistical difference [9.30% (4/43) vs 34. 88% (15/43) ; X²=8.17, P <0. 01].
JSR had better effect for preventing and treating moderate and severe acute radiation esophagitis in concurrent chemoradiotherapy induced esophageal carcinoma patients.
观察解毒生肌方防治食管癌放疗患者急性放射性食管炎的疗效。
将86例中晚期食管癌患者按随机数字表法分为治疗组和对照组，每组43例。所有患者均接受同步放化疗。治疗组患者从放疗开始服用解毒生肌方，每日1剂，连续服用8周；对照组患者在放疗前及放疗后30分钟内服用地塞米松、利多卡因和庆大霉素混合液，每次10 mL，放疗结束停药。观察两组急性放射性食管炎的发生时间、症状持续时间、食管放射性损伤程度、疗效、卡氏功能状态评分（KPS）改善率及不良反应发生率。
与对照组比较，治疗组急性放射性食管炎发生时间延长（15.46±3.37天 vs 10.23±2.46天），症状持续时间缩短（20.18±4.56天 vs 26.17±3.26天），差异有统计学意义（P<0.01）。治疗组中、重度（Ⅱ度至Ⅳ度）急性放射性食管炎发生率低于对照组（Z=3.34，P<0.01）。治疗组总有效率为95.35%（41/43），对照组为67.44%（29/43），两组比较差异有统计学意义（X²=11.06，P<0.01）。治疗组KPS改善率高于对照组[65.12%（28/43） vs 27.91%（12/43）；X²=11.97，P<0.01]。治疗组不良反应发生率低于对照组，差异有统计学意义[9.30%（4/43） vs 34.88%（15/43）；X²=8.17，P<0.01]。
解毒生肌方对同步放化疗食管癌患者中重度急性放射性食管炎有较好防治作用。
